Get the Stockscreener App
0.9365
1.50%
-0.0143
After Hours:
.93
-0.0065
-0.69%
Cognition Therapeutics Inc stock is traded at $0.9365, with a volume of 536.75K.
It is down -1.50% in the last 24 hours and down -9.08% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$0.9508
Open:
$0.98
24h Volume:
536.75K
Relative Volume:
0.54
Market Cap:
$89.06M
Revenue:
-
Net Income/Loss:
$-19.58M
P/E Ratio:
-3.6341
EPS:
-0.2577
Net Cash Flow:
$-20.25M
1W Performance:
-9.95%
1M Performance:
-9.08%
6M Performance:
-15.63%
1Y Performance:
-25.67%
1-Day Range:
$0.9335
$0.98
1-Week Range:
$0.93
$1.075
52-Week Range:
$0.5501
$2.05
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.9365 | 89.06M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Cognition Therapeutics, Inc.Common Stock (Nasdaq:CGTX) Detailed Stock Data - The Chronicle-Journal
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
MU: Micron Technology Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA aligns with Cognition on pivotal DLB psychosis trial - scanx.trade
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
CGTX Q2 2026 Earnings: Narrower-Than-Expected Loss Provides Positive Surprise, Shares SlipFinancial Health Score - dars.gov.et
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup: the $0.93 to $1.03 Range Remains in Focus under the Current SnapshotIPO Entry Watch - vinanet.vn
Cognition (CGTX) Today: Moves 1.14% Lower to $0.98 for the Current Session; Technical Setup - dars.gov.et
Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn
Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Cognition (CGTX) Close in Focus: Ends Down by 3.33% at $0.99; Chart Reference: Price Remains Between $0.94 Support and $1.04 Resistance in the Current UpdateOpening Range Breakout - careplusvn.com
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Cognition Therapeutics (CGTX) Edges Higher as Traders Eye Key Resistance LevelsBearish Sentiment - careplusvn.com
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3%Time to Buy? - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
CGTX|Cognition Therapeutics Inc|Price:1.020|Chg%:-0.040 - tradingkey.com
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
CGTX|Cognition Therapeutics Inc|Price:0.982|Chg%:-0.038 - TradingKey
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress in Alzheimer’s PipelineLong-Term Guidance - dars.gov.et
Cognition Therapeutics (CGTX) Slips 4% as Support Level Comes Into FocusBreakout Confirmation - dars.gov.et
Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr
CGTX Q1 2026 Earnings: Narrower Loss Bolsters Cash Runway as Alzheimer’s Trials ContinueGuidance Revision Trend - dars.gov.et
CGTX Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesEarnings Power Value - careplusvn.com
Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):